DIAGNOSTICS

page. LEARNING GUIDE: CARDIAC 50 Table 5-3. Biomarker Recommendations in the 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guidelines for the Management of Heart Failure56 STRENGTH OF RECOMMENDATION USE RECOMMENDATION AND LEVEL OF EVIDENCE TO SUPPORT RECOMMENDATION The NP biomarkers are recommended for supporting Strong recommendation for use DIAGNOSIS or excluding a diagnosis of with high-quality evidence HF in a patient who presents Is recommended with dyspnea In chronic HF, a BNP or Strong recommendation for use NT-proBNP measurement is with high-quality evidence recommended for determining Is recommended prognosis or disease severity In AHF, measurement of an NP and/or cardiac troponin at Strong recommendation for use the time of hospital admission with high-quality evidence is recommended to provide Is recommended prognostic information PROGNOSIS OR RISK STRATIFICATION Moderate recommendation for During hospitalization for HF, use (reasonable to use) with a measurements of a predischarge moderate quality of evidence NP level is reasonable to establish from non-randomized trials* a prognosis after discharge Is reasonable In chronic HF, it may be Weak recommendation for use reasonable to use other clinically (may be reasonable to use) with available tests (e .g ., biomarkers of a moderate quality of evidence fibrosis or myocardial injury)
